Compare · GNLX vs NVO
GNLX vs NVO
Side-by-side comparison of Genelux Corporation (GNLX) and Novo Nordisk A/S (NVO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both GNLX and NVO operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO is the larger of the two at $173.66B, about 1547.7x GNLX ($112.2M).
- Over the past year, GNLX is down 58.4% and NVO is down 28.6% - NVO leads by 29.8 points.
- NVO has hit the wire 4 times in the past 4 weeks while GNLX has been quiet.
- NVO has more recent analyst coverage (25 ratings vs 6 for GNLX).
- Company
- Genelux Corporation
- Novo Nordisk A/S
- Price
- $2.42-2.02%
- $38.82-1.05%
- Market cap
- $112.2M
- $173.66B
- 1M return
- -4.35%
- -10.14%
- 1Y return
- -58.42%
- -28.57%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- 2023
- News (4w)
- 0
- 4
- Recent ratings
- 6
- 25
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Latest GNLX
- Genelux Announces Publication of a Deep and Durable Response in a Platinum-relapsed Small Cell Lung Cancer Patient Following Systemically Delivered Olvi-Vec-Primed Immunochemotherapy
- President and CEO Zindrick Thomas sold $91,899 worth of shares (34,463 units at $2.67), decreasing direct ownership by 3% to 1,226,427 units (SEC Form 4)
- Chief Scientific Officer Yu Yong sold $26,658 worth of shares (9,683 units at $2.75), decreasing direct ownership by 4% to 258,688 units (SEC Form 4)
- Chief Technical Officer Cappello Joseph sold $28,112 worth of shares (10,257 units at $2.74), decreasing direct ownership by 3% to 318,480 units (SEC Form 4)
- Genelux Corporation Reports Second Quarter Financial Results and Provides Business Updates
- SEC Form 10-Q filed by Genelux Corporation
- Chief Technical Officer Cappello Joseph sold $1,924 worth of shares (653 units at $2.95), decreasing direct ownership by 0.20% to 328,737 units (SEC Form 4)
- President and CEO Zindrick Thomas sold $8,905 worth of shares (3,023 units at $2.95), decreasing direct ownership by 0.24% to 1,260,890 units (SEC Form 4)
- Chief Scientific Officer Yu Yong sold $1,922 worth of shares (653 units at $2.94), decreasing direct ownership by 0.24% to 268,371 units (SEC Form 4)
- Attovia Therapeutics Appoints John W. Smither to Board of Directors
Latest NVO
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- Novo Nordisk A/S downgraded by Morgan Stanley with a new price target
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- Novo Nordisk A/S downgraded by Deutsche Bank